

● SIDE-EFFECTS

- ▶ **Common or very common** Anxiety · appetite decreased · constipation · diarrhoea · dizziness · drowsiness · dry mouth · fall · fatigue · flushing · gastrointestinal discomfort · gastrointestinal disorders · headache · muscle complaints · nausea · pain · palpitations · paraesthesia · sexual dysfunction · skin reactions · sleep disorders · sweat changes · tinnitus · tremor · urinary disorders · vision disorders · vomiting · weight changes · yawning
- ▶ **Uncommon** Apathy · arrhythmias · behaviour abnormal · burping · chills · concentration impaired · disorientation · dysphagia · ear pain · feeling abnormal · gait abnormal · haemorrhage · hepatic disorders · hyperglycaemia · increased risk of infection · malaise · menstrual disorder · movement disorders · mydriasis · peripheral coldness · photosensitivity reaction · postural hypotension · suicidal tendencies · syncope · taste altered · temperature sensation altered · testicular pain · thirst · throat tightness · vertigo
- ▶ **Rare or very rare** Angioedema · cutaneous vasculitis · dehydration · galactorrhoea · glaucoma · hallucination · hyperprolactinaemia · hypertensive crisis · hyponatraemia · hypothyroidism · mania · menopausal symptoms · oral disorders · seizure · serotonin syndrome · SIADH · Stevens-Johnson syndrome · urine odour abnormal

SIDE-EFFECTS, FURTHER INFORMATION Symptoms of sexual dysfunction may persist after treatment has stopped.

- **PREGNANCY** Toxicity in *animal* studies—avoid in patients with stress urinary incontinence; in other conditions use only if potential benefit outweighs risk. Risk of neonatal withdrawal symptoms if used near term.

- **BREAST FEEDING** Present in milk—manufacturer advises avoid.

- **HEPATIC IMPAIRMENT** Manufacturer advises avoid.

- **RENAL IMPAIRMENT** Avoid if eGFR less than 30 mL/minute/1.73 m².

- **TREATMENT CESSATION** Nausea, vomiting, headache, anxiety, dizziness, paraesthesia, sleep disturbances, and tremor are the most common features of abrupt withdrawal or marked reduction of the dose; dose should be reduced over at least 1–2 weeks.

● NATIONAL FUNDING/ACCESS DECISIONS

CYMBALTA[®]

Scottish Medicines Consortium (SMC) decisions

- ▶ With oral use for Diabetic neuropathy The *Scottish Medicines Consortium* has advised (September 2006) that duloxetine (Cymbalta[®]) should be restricted for use by specialists when other treatments for diabetic peripheral neuropathic pain are unsuitable or inadequate.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Gastro-resistant capsule

CAUTIONARY AND ADVISORY LABELS 2

▶ Duloxetine (Non-proprietary)

Duloxetine (as Duloxetine hydrochloride) 20 mg Duloxetine 20mg gastro-resistant capsules | 28 capsule [PoM] £18.48 DT = £2.56

Duloxetine (as Duloxetine hydrochloride) 30 mg Duloxetine 30mg gastro-resistant capsules | 28 capsule [PoM] £22.40 DT = £1.63

Duloxetine (as Duloxetine hydrochloride) 40 mg Duloxetine 40mg gastro-resistant capsules | 56 capsule [PoM] £36.96 DT = £4.57

Duloxetine (as Duloxetine hydrochloride) 60 mg Duloxetine 60mg gastro-resistant capsules | 28 capsule [PoM] £27.72 DT = £2.33

▶ Cymbalta (Eli Lilly and Company Ltd)

Duloxetine (as Duloxetine hydrochloride) 30 mg Cymbalta 30mg gastro-resistant capsules | 28 capsule [PoM] £22.40 DT = £1.63

Duloxetine (as Duloxetine hydrochloride) 60 mg Cymbalta 60mg gastro-resistant capsules | 28 capsule [PoM] £27.72 DT = £2.33

▶ Depalta (Disposable Medical Equipment Ltd)

Duloxetine (as Duloxetine hydrochloride) 30 mg Depalta 30mg gastro-resistant capsules | 28 capsule [PoM] £2.95 DT = £1.63

Duloxetine (as Duloxetine hydrochloride) 60 mg Depalta 60mg gastro-resistant capsules | 28 capsule [PoM] £4.25 DT = £2.33

▶ Duciltila (Aristo Pharma Ltd)

Duloxetine (as Duloxetine hydrochloride) 30 mg Duciltila 30mg gastro-resistant capsules | 28 capsule [PoM] £22.40 DT = £1.63

Duloxetine (as Duloxetine hydrochloride) 60 mg Duciltila 60mg gastro-resistant capsules | 28 capsule [PoM] £27.72 DT = £2.33

▶ Dutor (Torrent Pharma (UK) Ltd)

Duloxetine (as Duloxetine hydrochloride) 20 mg Dutor 20mg gastro-resistant capsules | 28 capsule [PoM] £18.48 DT = £2.56

Duloxetine (as Duloxetine hydrochloride) 30 mg Dutor 30mg gastro-resistant capsules | 28 capsule [PoM] £22.40 DT = £1.63

Duloxetine (as Duloxetine hydrochloride) 40 mg Dutor 40mg gastro-resistant capsules | 56 capsule [PoM] £36.96 DT = £4.57

Duloxetine (as Duloxetine hydrochloride) 60 mg Dutor 60mg gastro-resistant capsules | 28 capsule [PoM] £27.72 DT = £2.33

▶ Yentreve (Eli Lilly and Company Ltd)

Duloxetine (as Duloxetine hydrochloride) 20 mg Yentreve 20mg gastro-resistant capsules | 28 capsule [PoM] £18.48 DT = £2.56

Duloxetine (as Duloxetine hydrochloride) 40 mg Yentreve 40mg gastro-resistant capsules | 56 capsule [PoM] £36.96 DT = £4.57

Venlafaxine

17-Jul-2019

- **DRUG ACTION** A serotonin and noradrenaline re-uptake inhibitor.

● INDICATIONS AND DOSE

Major depression

▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

- ▶ **Adult:** Initially 75 mg daily in 2 divided doses, then increased if necessary up to 375 mg daily, dose to be increased if necessary at intervals of at least 2 weeks, faster dose titration may be necessary in some patients; maximum 375 mg per day

▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

- ▶ **Adult:** Initially 75 mg once daily, increased if necessary up to 375 mg once daily, dose to be increased if necessary at intervals of at least 2 weeks, faster dose titration may be necessary in some patients; maximum 375 mg per day

Generalised anxiety disorder

▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

- ▶ **Adult:** 75 mg once daily, increased if necessary up to 225 mg once daily, dose to be increased at intervals of at least 2 weeks; maximum 225 mg per day

Social anxiety disorder

▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

- ▶ **Adult:** 75 mg once daily, there is no evidence of greater efficacy at higher doses, increased if necessary up to 225 mg once daily, dose to be increased if necessary at intervals of at least 2 weeks; maximum 225 mg per day

Panic disorder


▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

- ▶ **Adult:** Initially 37.5 mg once daily for 7 days, increased to 75 mg once daily, increased if necessary up to 225 mg once daily, dose to be increased at intervals of at least 2 weeks; maximum 225 mg per day

Menopausal symptoms, particularly hot flushes, in women with breast cancer

▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

- ▶ **Adult:** 37.5 mg once daily for one week, then increased if necessary to 75 mg once daily

- **UNLICENSED USE** [EvGr] Venlafaxine is used for menopausal symptoms,  but it is not licensed for this indication.

- **CONTRA-INDICATIONS** Uncontrolled hypertension

- **CAUTIONS** Conditions associated with high risk of cardiac arrhythmia · diabetes · heart disease (monitor blood pressure) · history of bleeding disorders · history of epilepsy · history or family history of mania · susceptibility to angle-closure glaucoma

- **INTERACTIONS** → Appendix 1: venlafaxine